Modeling and Simulation - PK/PD Archives | Page 18 of 37

Publication

Modeling & Simulation Relating Survival to Tumor Growth Inhibition in Patients

The published OS model and resultant simulations can be leveraged to support Phase II design…

Certara2015年9月1日

Knowledge Base

Derivation for Logarithmic Trapezoidal AUC Calculation

Calculating area under the curve requires the use of two separate equations: one is follows…

Certara2015年8月5日

Publication

Synthesis and Pharmacokinetic Evaluation of Siderophore Biosynthesis Inhibitors for Mycobacterium Tuberculosis

Certara2015年7月23日

Publication

Population Pharmacokinetic Modeling of Motesanib and Its Active Metabolite, M4, in Cancer Patients

Motesanib is a small molecule and potent multikinase inhibitor with antiangiogenic and antitumor activity. Population…

Certara2015年7月23日

Publication

Population Pharmacokinetic Analysis of Thrombomodulin Alfa to Support Dosing Rationale in Patients with Renal Impairment

Thrombomodulin alfa is a soluble recombinant human thrombomodulin that was reported to enhance the reversal…

Certara2015年5月1日

Publication

Does Age Affect Gastric Emptying Time? A Model-based Meta-analysis

Gastric emptying (GE) is often reported to be slower and more irregular in premature neonates than…

Certara2015年5月1日

Blog

小児への投薬用量：小さな患者のための大きな問題への取り組み

小児薬開発における課題とその複雑さは、広く認識されています。Pharmacometric modeling and simulation (M&S)…

Certara2015年4月23日

Publication

Effect of Age and Sex on the Pharmacokinetics and Safety of Avibactam in Healthy Volunteers

Avibactam is a novel non-β-lactam β-lactamase inhibitor currently being assessed in combination with ceftazidime, ceftaroline…

Certara2015年4月1日

Publication

Modeling and Simulation to Support Phase 2 Dose Selection for RG7652, a Fully Human Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9

RG7652 is a fully humanized monoclonal antibody targeting human PCSK9, a regulator of serum low…

Certara2015年3月31日

Publication

Safety and Pharmacokinetics of Single and Multiple Ascending Doses of Avibactam Alone and in Combination with Ceftazidime in Healthy Male Volunteers: Results of Two Randomized, Placebo-controlled Studies

Avibactam is a novel non-β-lactam β-lactamase inhibitor effective against Ambler class A, C and some…

Certara2015年3月27日

Powered by Translations.com GlobalLink Web Software

Modeling and Simulation – PK/PD

Modeling & Simulation Relating Survival to Tumor Growth Inhibition in Patients

Derivation for Logarithmic Trapezoidal AUC Calculation

Synthesis and Pharmacokinetic Evaluation of Siderophore Biosynthesis Inhibitors for Mycobacterium Tuberculosis

Population Pharmacokinetic Modeling of Motesanib and Its Active Metabolite, M4, in Cancer Patients

Population Pharmacokinetic Analysis of Thrombomodulin Alfa to Support Dosing Rationale in Patients with Renal Impairment

Does Age Affect Gastric Emptying Time? A Model-based Meta-analysis

小児への投薬用量：小さな患者のための大きな問題への取り組み

Effect of Age and Sex on the Pharmacokinetics and Safety of Avibactam in Healthy Volunteers

Modeling and Simulation to Support Phase 2 Dose Selection for RG7652, a Fully Human Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9

Safety and Pharmacokinetics of Single and Multiple Ascending Doses of Avibactam Alone and in Combination with Ceftazidime in Healthy Male Volunteers: Results of Two Randomized, Placebo-controlled Studies

メルマガ登録

クイックアクセス

ソリューション

お問合せ